SU10944

Overview

SU10944 is a selective, orally active VEGFR inhibitor, with an IC 50 of 6 nM against VEGFR-1 , an IC 50 of 96 nM and a K i of 21 nM against VEGFR-2 . SU10944 only exhibits weak inhibitory activity against PDGFRβ ( IC 50 = 1 μM), SCFR ( IC 50 = 1.58 μM) and FGFR-1 ( IC 50 = 1.6 μM). SU10944 selectively inhibits VEGFR receptor downstream signaling, neovascularization, vascular permeability, VEGF-mediated tissue factor production, and induces tumor growth delay. SU10944 can be used in research related to diabetic retinopathy, exudative age-related macular degeneration or cancer .

Application

Products | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Retinopathy | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Visual System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > FGFR

Product Information

• Catalog No.: HY-135435
• CAS No.: 515821-11-1
• Molecular Formula: C17H16N2O3
• Molecular Weight: 296.33
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source